<img height="1" width="1" style="display:none;" alt="" src="https://dc.ads.linkedin.com/collect/?pid=217082&amp;fmt=gif">

MD Biosciences Blog

MD Biosciences

Find me on:

Recent Posts

Preclinical Imiquimod-induced Psoriasis-like Skin Inflammation Model

Posted by MD Biosciences on May 1, 2012 2:12:00 PM

A Rapid 10 day preclinical efficacy study that produces lesions highly representative of human psoriatic lesions.

Wednesday, May 2, 2012, St. Paul, MN – The most common models for evaluating skin-related inflammation are time consuming and expensive. While they provide valuable data, they don’t allow for rapid and cost effective evaluation of therapeutics earlier in the preclinical pipeline. In response to this need for more convenient and cost effective models, researchers (Van der Fits et al, 2009) developed a model using Imiquimod (IMQ) to induce psoriasis-like inflammation.

Imiquimod is a potent immune activator that is traditionally used to treat virus-associated skin abnormalities and precancerous skin lesions. However it can exacerbate psoriasis (both at the treated area and at distant skin sites) during topical treatment. Application of IMQ to mouse skin results in the influx of various cells of the immune system as well as hyperplasia of the epidermis that is critically dependent on IL-23 and IL-17.

MD Biosciences now offers the IMQ-induced model of skin inflammation as part of its portfolio of efficacy services. The model is 10 days long and the lesions closely resemble that of human psoriatic lesions with erythema, skin thickening and epidermal alterations such as acanthosis and parakeratosis. Subjects are given a psoriasis score depending on the degree of erythema, scaling and thickening. Analysis includes clinical score of the back, ear thickness and histology of both the ear and back.

 

Image: histology on psoriatic lesions (B-D) compared to that of a naive sample (A) in the IMQ-induced model of skin inflammation. For additional data, please visit the IMQ-induced model.

histology of the skin in the IMQ-induced psoriasis-like model of skin inflammation, preclinical CRO

 

About MD Biosciences

MD Biosciences is a Preclinical Contract Research Organization (CRO) providing services and products for biotech/pharmaceutical, medical device and animal health and companies engaged in inflammations & neurology research. With specialized laboratories located in Minnesota, Glasgow, and Israel, our panel of internationally recognized experts provides in-depth expertise and technologies to overcome challenges and provide total solutions to the drug discovery market.

--------

 

The information in this press release should be considered accurate only as of the date of the release. MDB has no intention of updating and specifically disclaims any duty to update the information in these press releases.

Read More

Topics: Dermal

Preclinical Efficacy Models of Parkinson's Disease: 6OHDA & Acute MPTP

Posted by MD Biosciences on Aug 11, 2011 10:03:00 PM

MD Biosciences, a Preclinical Contract Research Organization (CRO), offers in vivo models for the study of Parkinson's Disease (PD). The 6-OHDA and acute MPTP models for PD have been well characterized with the underlying mechanisms of toxicity well understood. Both models are useful tools in evaluating potential neuroprotective therapies providing the ability to target any differences in motor activities and determine whether a drug differentially affects a specific motor behavior.

Parkinson's Disease Background 
Parkinson's Disease (PD) is typically an adult-onset progressive neurodegenerative movement disorder that affects millions of people worldwide. Pathologically, PD is characterized by the profound and specific loss of dopaminergic (DAergic) neurons in the substantia nigra pars compacta (SNpc) of the midbrain. Other areas interconnected with the SNpc, the caudate and putamen, collectively known as the striatum, also show remarkable loss of their projection fibers. In accordance with insult to brain regions involved in controlling coordinated movements, the cardinal symptoms of PD include bradykinesia, resting tremor, rigidity, and postural instability. Due to its complex pathology, however, no disease model has yet to faithfully replicate all aspects of human PD. Converging lines of evidence from toxin-induced and genetic models have continued to further our understanding of the pathological processes underlying PD and lend themselves as useful systems for the examination of therapeutic interventions.

PD Whitepaper & Preclinical Efficacy Studies 
MD Biosciences has released a new whitepaperdiscussing the various efficacy models of PD, the underlying mechanisms of each model and their usefulness as tools for the development of new therapies and interventions. Additionally, MD Biosciences offers these classical models of PD as contracted research studies as part of our portfolio of Neurology Discovery Services. A copy of the whitepaper "What in vivo models have revealed about the pathogenesis and treatment of PD" can be downloaded at http://www.mdbiosciences.com

About MD Biosciences 
MD Biosciences is a Preclinical Contract Research Organization (CRO) providing services and products for biotech/pharmaceutical, medical device and animal health and companies engaged in inflammations & neurology research. With specialized laboratories located in Minnesota, Glasgow, and Israel, our panel of internationally recognized experts provides in-depth expertise and technologies to overcome challenges and provide total solutions to the drug discovery market.

The information in this press release should be considered accurate only as of the date of the release. MD Biosciences has no intention of updating and specifically disclaims any duty to update the information in these press releases.

Read More

Topics: Neuro/CNS, Parkinsons, Models, efficacy

eBook: Pain & Inflammation Link | Targets in the Overlap

Posted by MD Biosciences on Jul 13, 2011 9:59:00 PM

MD Biosciences, a preclinical CRO focused in pain and inflammations, has released a new eBook discussing the interactions between the nervous and immune systems and the drug targets that may lie in the overlap. This newly published eBook is meant to be a review of the immune system and inflammation as it relates to pain, specifically neuropathic pain and covers the following: 

  •     Immune system and Inflammation
  •     Pain processing and Neuropathic Pain
  •     Cell types involved in neuro-inflammation aspect of neuropathic pain
  •     Potential inflammation-related drug targets for neuropathic pain
  •     Relevant preclinical models for neuropathic pain

 

Neuropathic pain presents a wide variety of challenges to researchers, not the least of which is the simple fact that neuropathic pain, by definition, requires neuronal damage, which in turn automatically initiates an immune response that often inflicts further damage.

The interactions between the immune and nervous systems in the case of neuropathic pain make for a very complex story that is only beginning to unfold. Fortunately, a variety of good preclinical neuropathic pain models for the simulation of neuropathic pain in humans have been used for some time and enable researchers to advance our understanding of disease mechanisms in the preclinical setting. Currently, existing pharmacological treatments for neuropathic pain, which address predominately neuronal targets, include opioid analgesics, tricyclic antidepressants and cation channel blockers among others. However these drugs treat symptoms and thus only provide temporary relief and are fraught with undesirable side effects such as tolerance and dependence. As the field of neuroimmunology progresses, it is possible that inflammation-associated drug targets may open to new and more effective treatments for neuropathic pain.

About MD Biosciences 
MD Biosciences is a Preclinical Contract Research Organization (CRO) providing services biotech/pharmaceutical, medical device and animal health and companies engaged in inflammations, neurology, pain and cardiovascular research. Our scientists are specialized and focused within these areas to provide a deep understanding of mechanisms involved, which enables them to contribute to study design and recommendations. We understand the challenges of filling and progressing product pipelines with limited budgets, time and resources. We also understand the importance of choosing a preclinical CRO that is the right fit with your organization. You’ll find that when working with MD Biosciences, we are focused on the science behind your programs to enable smarter and more efficient study designs aimed to meet your objectives.

The information in this press release should be considered accurate only as of the date of the release. MD Biosciences has no intention of updating and specifically disclaims any duty to update the information in these press releases. The eBook is meant to be an overview and should not be taken as comprehensive or definitive.

###

Read More

Topics: Pain, Inflammation

High ArthritoMabTM Antibody Cocktail Activity | 18-day RA Model Balb/c Mice

Posted by MD Biosciences on Feb 3, 2011 10:05:00 PM

MD Biosciences, a global biotechnology company focused in inflammations research, has optimized ArthritoMabTM Antibody Cocktail for the induction of arthritis in C57Bl/6. Using the optimized ArthritoMab Antibody Cocktail, investigators can induce arthritis in C57Bl/6 strains with as little as 2 mg of antibody and see good clinical disease scores as well as pannus formation, bone erosion, hyperplasia and cellular infiltration at the histological level. A detailed whitepaper covering the ArthritoMabTM antibody cocktail, protocols and data using various strains and positive control is available for complimentary download.

The optimized ArthritoMabTM antibody cocktail relies on the same four clones of antibody selected for use in the original cocktail, allowing researchers to continue to obtain comparative data without introducing unknown variables caused by additional antibody clones. The monoclonal antibody clones in the cocktail were selected to bind to C1, J1, U1 and D3 epitopes, which are well documented epitopes associated with arthritis in the collagen-induced arthritis (CIA) model. These epitopes are also spread across the entire CII region (fragments CB8, CB10 and CB11) to encourage better immune complex formation on the cartilage surface for initiation of arthritis.

With the increase in use of transgenic strains such as C57Bl/6 for the study of arthritis, investigators are often faced with low incidence rates in the CIA model. Alternatively, while the Collagen antibody-induced arthritis (CAIA) has been a good alternative for increasing the rates of incidence, often times the amount of antibody required in C57 strains is cost prohibitive. MD Bioproducts has optimized the ArthritoMabTM antibody cocktail enabling investigators to achieve high incidence rates (100%) in C57 strains while controlling costs in the amount of antibody required (as little as 2 mg of Antibody).

For years, the CIA model has been the standard for arthritis studies. Issues such as length of model, staggered disease onset, low disease induction, lab to lab variations, number of administration timepoints and clinical scoring periods caused researchers to look for a viable alternative. The collagen antibody induced arthritis model (AIA or CAIA) using ArthritoMabTM Antibody Cocktail is a reliable alternative providing results in just 12 days, high rates of incidence and synchronized disease onset.

About MD Biosciences 
MD Biosciences provides products and pre-clinical services for companies engaged in inflammations and neurology research. The company is headquartered in Switzerland under Morwell Diagnostics and has specialized laboratories located in Minnesota, Glasgow, and Israel. A panel of scientific experts provides companies’ in-depth expertise and technologies to tackle problems and provide flexible drug discovery solutions, enabling smarter results faster.

About MD Bioproducts 
MD Bioproducts is a division of MD Biosciences offering products in inflammation, neurology, cancer and immunology research. For those who have internal in vivo capabilities, MD Bioproducts makes available the ArthritoMabTM Antibody cocktail along with full technical support for establishing the protocol in house. For additional information on products offered, visit http://www.mdbioproducts.com.

The information in this press release should be considered accurate only as of the date of the release. MD Biosciences has no intention of updating and specifically disclaims any duty to update the information in these press releases.

# # #

Read More

Topics: Inflammation

Occlusion-induced Myocardial Infarct Model Studies Cardio Protection

Posted by MD Biosciences on Jun 16, 2010 11:21:00 AM

Wednesday, June 16, 2010, St. Paul, MN - MD Biosciences, a Preclinical Contract Research Organization (CRO), offers in vivo models for the study of myocardial infarct (MI). The occlusion-induced myocardial infarct model is a well-known technique for investigating the cardio-protection of a drug therapy in the event of ischemia/reperfusion injury. The advantage of the model is the ability to study the functional relevance of a drug treatment on the heart following direct coronary flow and the mechanisms by which the drug promotes myocardial protection.

 

Occlusion-induced Ischemia Reperfusion Injury

Occlusion of the left coronary artery is performed to mimic myocardial infarction in humans that results from occlusion of arteriosclerotic plaques of coronary arteries. Using this model, scientists can get a better understanding of the functional, structural and molecular changes associated with clinical ischemic heart disease as well as investigate the cardio-protection of potential drug therapies. Following the 45 minutes of LAD occlusion, the LAD is opened and coronary blood flow is allowed. Therefore, any IV dosed drug will reach the heart tissue and the infarct area immediately.

Myocardial Infarct model: preclinical contract research

 

Figure: Histology on four heart tissue samples from a vehicle treated group (A-B) and an active compound group (C-D) in the occlusion-induced ischemia reperfusion injury model. Occlusion duration was 45 minutes and reperfusion was over 48 hours. Slides A-D: transverse section of the heart at 0.5x magnification. Slides E-H: 4x magnification of slides A-D showing the scarred myocardium.

 

Study design can be customized to determine the duration of reperfusion following a 45-minute occlusion period. Readouts of the occlusion-induced ischemia-reperfusion injury model include histology of the heart as well as CPK and Troponin levels, which are relevant blood markers of myocardial infarction.

 

For more information and data on the occlusion-induced IR injury model, download the Whitepaper Myocardial Infarct models for evaluating the myocardial protection or potential drug therapies.

 

About MD Biosciences

MD Biosciences is a Preclinical Contract Research Organization (CRO) providing services and products for biotech/pharmaceutical, medical device and animal health and companies engaged in inflammations & neurology research. With specialized laboratories located in Minnesota, Glasgow, and Israel, our panel of internationally recognized experts provides in-depth expertise and technologies to overcome challenges and provide total solutions to the drug discovery market.

 

--------

 

The information in this press release should be considered accurate only as of the date of the release. MDB has no intention of updating and specifically disclaims any duty to update the information in these press releases.

 

 

Read More

Topics: Cardiovascular

MD Biosciences Launches New Products Division - MD Bioproducts

Posted by MD Biosciences on Oct 6, 2009 10:45:00 AM

MD Biosciences (MDB)  launches MD  Bioproducts, a division of MD Biosciences, in a continued effort to  meet client needs for high quality research products. The new division allows MD Biosciences to strengthen and expand it's product offering for immunology and cell biology research while maintaining its contract research focus within inflammation and neurology disease research.

While MD Biosciences has offered its products for purchase since 1991, the new division permits for increased product distribution by 140 percent. Cell Culture Related Reagents, Assays, Antibodies, Proteins, and Western Blot kits are some of the products MD Bioproducts currently provides. Currently, new products and product technologies are being explored and will be added to the development and manufacturing for the coming year.

"At MD Biosciences, our top priority has always been meeting the needs of our clients through the products we offer and customer experience we deliver. The launch of MD Bioproducts is a great step of convenience for our clients-accommodating them to optimize their research process. We know that our products offer accuracy and reproducibility so our clients can be confident in their results. Our quality reagents contribute to the success of our clients' research," stated MD Biosciences President, Eddie Moradian.

Apart from the key benefit of increased manufacturing opportunities, the new division provides a better resource for product purchasers. VP of Marketing & Sales, Amy Clausen said, "MD Bioproducts showcases a new, clean look--including packaging, logo and its own website, which allows for easy navigation and viewing of product features. We are thrilled to be taking this direction at MDB as it will simplify and improve the customer experience for the client." MD Bioproducts website may be visited at www.mdbioproducts.com.


About MD Biosciences

MD Biosciences provides contract research services including efficacy testing, mode of action platforms, in vitro analysis, and histology for the Pharmaceutical, Medical Device and Animal Health & Nutrition Industries. We offer several novel models in the area of rheumatoid arthritis (RA), Multiple sclerosis, asthma, IBD, pain, and Parkinson's disease. The in-depth expertise in these disease models has been applied to designing protocols to assess the efficacy and required dosage of novel compounds. Contracted studies are designed and reviewed by MDB’s panel of internationally recognized experts and performed at one of MDB’s specialized laboratories located in St. Paul, MN (USA), Glasgow (Scotland) or in Israel. We provide a ready team of experts to tackle problems and provide solutions.

About MD Bioproducts

MD Bioproducts is a division of MD Biosciences offering high-quality reagents for immunology and cell biology research. Our goal is to provide products that are easy-to-use, accurate and reproducible – ultimately contributing to our client's research success.

###



The information in this press release should be considered accurate only as of the date of the release. MDB has no intention of updating and specifically disclaims any duty to update the information in these press releases.
Read More

Topics: Research Products

PharmaGap & MD Biosciences Pursue Novel Inflammatory & Neuro PKC Theta Inhibitor

Posted by MD Biosciences on Mar 16, 2009 10:58:00 AM


Zurich, Switzerland & Ottawa, Canada, March 16, 2009 – PharmaGap Inc. (TSX-V: GAP)

(“PharmaGap” or “the Company”) and MD Biosciences GmbH (“MD Biosciences”) have entered into a co-development collaboration pertaining to novel compounds for therapeutic usage in inflammatory and neurological applications, including potentially arthritis and multiple sclerosis. MD Biosciences has been granted exclusive access to a series of novel peptide compounds designed by PharmaGap as inhibitors of protein kinase c theta (“PKC theta”). PKC theta is a cellular signaling molecule associated with processes believed to contribute to many inflammatory and neurological disease conditions. MD Biosciences will assess the PharmaGap compounds in order to characterize their activity against PKC theta and then identify specific disease conditions in the areas of inflammation and neurology where the compounds may prove to be of therapeutic value. MD Biosciences would act as the lead partner to then commercialize the compounds for these specific therapeutic indications. Commercialization rights on generated intellectual property will be shared by the companies. Details of the agreement remain confidential.

 

MD Biosciences is a Swiss-based preclinical contract research and drug development company with numerous technology platforms and a core focus in Inflammation and Neurology Research. The Drug Discovery division is focused on developing early stage drug compounds for therapeutic applications within inflammation and neurology. MD Biosciences’ strategy is to develop a series of novel drug compounds suitable for out-licensing to larger pharmaceutical industry partners. MD Biosciences operates facilities in Switzerland, the UK, the U.S. and Israel.

 

Dr. Eddie Moradian, Chief Executive of MD Biosciences, said, “We are extremely pleased to establish this collaboration with PharmaGap. The application of our inflammation and neurology discovery platforms to PharmaGap’s novel peptide inhibitors of PKC theta will accelerate and maximize the potential for development and future commercialization for the resulting final compounds. Our knowledge of the inflammation and neurology field tells us that novel compounds targeting protein kinases and cell signaling are of great interest to the pharmaceutical industry”

 

Dr. Jenny Phipps, Chief Scientific Officer of PharmaGap, stated, “I am delighted and excited to continue working with the technical and scientific team at MD Biosciences. I believe that their expertise and technology will add immensely to our PKC theta development program, not only in the area of inflammation and neurology but also in providing key insights that can be used in our established cancer program.”

 

“We are very pleased that MD Biosciences has identified our inhibitor of PKC theta as a compound of interest to which they wish to apply development resources and technology” said Robert C. McInnis, President and C.E.O. of PharmaGap. “Their capabilities and technology platform will allow much quicker and more technologically efficient development of a potential therapeutic drug for use in inflammation and neurological disease, which is an area in which PharmaGap has not defined as being a core focus, thus leveraging the potential value for PharmaGap shareholders in the investment in our technology platform made to date. This collaboration allows us to expand the potential downstream value of the PKC theta compound into other diseases, while allowing us to maintain our clear focus on developing compounds for cancer. Furthermore, it demonstrates the value in the underlying concept of our Company’s research program, which is to produce a series of compounds targeting PKC isoforms based on a common drug design architecture.”

Protein Kinase C Theta

The protein kinase c family of cellular enzymes modulate important biochemical and genetic-based signaling pathways in cells. PKC theta is associated with cell signaling processes in inflammatory and neurological diseases, as well as in certain cancers.

 

About MD Biosciences GmbH

MD Biosciences (www.mdbiosciences.com) is a leading preclinical contract research organization (CRO) and drug development company focused in Inflammatory and Neurology Diseases. It’s novel technologies encompass in vivo and in vitro mechanism of action platforms, in vitro compound profiling, efficacy and proof-of-concept, as well as multiple end-point readouts including biomarker/gene expression analysis, imaging capabilities and histopathology. These technologies are currently being applied across the pharmaceutical, medical device and animal health and nutrition sectors.

 

The MD Biosciences drug discovery and development activities are funded privately by the Moradian-Shasha group with the objective of value creation through the discovery of novel compounds or the repositioning of existing compounds in new applications. MD Biosciences is open towards the negotiation of collaborations in defined areas and with companies having the same ideals and objectives.

 

About PharmaGap Inc.

PharmaGap Inc. (TSX-V: GAP), based in Ottawa, ON, is a biotechnology company with a core focus on developing novel therapeutic compounds for the treatment of cancer. PharmaGap's research platform targets cellular signalling pathways controlled by Protein Kinase C (PKC) isoforms. PharmaGap's lead drug compound, PhG-alpha-1, is in preclinical development. The Company's strategy is to out-license drug compounds to larger life sciences companies at the preclinical stage. For more information on PharmaGap please visit the Company's website at www.pharmagap.com.

 

For information relating to this Release, please contact:

 

Robert McInnis, President & CEO
PharmaGap Inc.
(613) 990-9551 bmcinnis@pharmagap.com

Dr. Eddie Moradian, President & CEO
MD Biosciences GmbH
(651) 641-2836 eddie@mdbiosciences.com

 

---------------

The information in this press release should be considered accurate only as of the date of the release. MD Biosciences has no intention of pudating and specifically disclaims any duty to update the information in this press release.

 

Read More

Lumican & Keratocan Monoclonal Antibodies | Eye/Cornea

Posted by MD Biosciences on Dec 9, 2008 11:12:00 AM


St Paul, MN, December 9, 2008 – MD Biosciences, a global biotechnology company focused in inflammations and neurology research, announces the launch of Lumican and Keratocan Monoclonal Antibodies. Both Lumican and Keratocan play a role in the development and maintenance of corneal transparency making them ideal for applications in Eye and Cornea Research.

 

Lumican and Keratocan belong to the Small Leucine Rich Proteoglycan (SLRP) family. Keratocan was originally found to be a cornea specific keratan sulphate proteoglycan. Lumican is a proteoglycan expressed in extracellular matrix (ECM) and connective tissues where it has been reported to contribute to collagen fibrillogenesis, tissue hydration, migration and proliferation. Lumican modified with keratan sulphate, constitutes one of the major proteoglycans of the corneal stroma, where it stimulates cell migration on the corneal epithelium and is also believed to play a regulatory role for keratocan. Mutations of keratocan cause cornea plana in humans, which is often associated with glaucoma, whereas the absence of Lumican leads to formation of cloudy corneas. This suggests that Keratocan and Lumican have different roles in regulating the formation of stromal extracellular matrix.

 

Both the Lumican Monoclonal Antibody (Catalog 1042007) and the Keratocan Monoclonal Antibody (Catalog 1042008) are IgM antibodies that are affinity purified on a thiophilic column. The Lumican antibody recognizes a protein epitope and is specific for human, bovine, mouse and porcine tissues. The keratocan antibody recognizes a protein core epitope and is specific for human, bovine, porcine, mouse and chicken tissues. Both antibodies are supplied as liquid, ready to use, at a concentration of 0.1 mg/mL for ELISA, Western Blot and IHC applications.

 

In addition to Lumican and Keratocan antibodies, MD Biosciences also supplies a line of Aggrecan, Collagen, MMP, Proteoglycan, Protease, and T cell specific reagents that encompass natural and recombinant proteins, antibodies, ELISAs and assays. For additional information on any of the reagents or services provided, please visit the website at www.mdbiosciences.com.

 

About MD Biosciences

MD Biosciences provides products and pre-clinical services for companies engaged in inflammations and neurology research. The company is headquartered in Switzerland under Morwell Diagnostics and has specialized laboratories located in Minnesota, Glasgow, and Israel. A panel of scientific experts provides companies’ in-depth expertise and technologies to tackle problems and provide flexible drug discovery solutions, enabling smarter results faster.

 

###

 

The information in this press release should be considered accurate only as of the date of the release. MD Biosciences has no intention of updating and specifically disclaims any duty to update the information in these press releases.

 

Read More

Topics: eye, cornea

MD Biosciences Showcases its Products & Services at APLAR Conference.

Posted by MD Biosciences on Sep 22, 2008 11:18:00 AM


St Paul, Minnesota, September 22, 2008 – MD Biosciences, a global biotechnology company focused in inflammations & neurology research will showcase its inflammations related pre-clinical services and research products at the 13th Congress of The Asia Pacific League of Associations for Rheumatology (APLAR) in Japan on September 23 – 27, 2008. APLAR focuses on providing state of the art care to patients with arthritis and other musculoskeletal diseases through continuing professional development of members, increasing the awareness and understanding about rheumatic diseases, patient advocacy and empowerment, and fostering research in the field of rheumatic diseases.

MD Biosciences, with roots in the sales of rheumatoid arthritis research reagents, will feature it’s capabilities in preclinical outsourcing services such as the Collagen-Induced Arthritis (CIA), Collagen Antibody-induced Arthritis (CAIA), Adjuvant Induced arthritis (AIA), Monoarthritic Pain, along with general inflammation assays and the Senerga® Mode of Action Platform. MD Biosciences offers customization of all protocols as well as end-point readouts such as biomarker analysis, histology, and gene expression analysis. MD Biosciences research products featured at the conference include collagen related reagents and assays, ArthritoMab™ antibody cocktail, ELISAs, Aggrecan antibodies and T-cell antibodies.

In addition to the product and service offerings within Arthritis, MD Biosciences also offers products and services within other therapeutic areas such as Multiple sclerosis, Respiratory, IBD, Type I Diabetes, Endotoxic shock, Contact Dermatitis, Inflammatory and Arthritic Pain, Gliosis, and Parkinson's Disease.

Our Inflammations Discovery Service offers quick start dates and timely delivery of data, specialized scientists with experience using small molecules and biologicals, standard and specialized routes of administration, customized protocols and the development of novel models.

About MD Biosciences
MD Biosciences provides products and pre-clinical services for companies engaged in inflammations and neurology research. The company is headquartered in Switzerland and has specialized laboratories located in the United States, United Kingdom, and Israel. A panel of scientific experts provides companies’ in-depth expertise and technologies to tackle problems and provide flexible drug discovery solutions, enabling smarter results faster.

###

 

The information in this press release should be considered accurate only as of the date of the release. MD Biosciences has no intention of updating and specifically disclaims any duty to update the information in these press releases.


Read More

MD Biosciences Offers Monoarthritic Pain Model

Posted by MD Biosciences on Sep 10, 2008 11:23:00 AM


MD Biosciences, a global biotechnology company focused in inflammations and neurology research, is expanding its line of arthritis and pain preclinical services with the addition of the CFA-induced monoarthritic pain model. The model offers advantages over traditional arthritis models in that disease develops in only one joint allowing a comparison to the healthy joint. The quantification of pain associated with arthritis can be useful in elucidating the mechanisms of arthritis as well as evaluating the efficacy of anti-arthritic drug compounds in the discovery phase.

The monoarthritic pain model is a 28-day model with arthritis and subsequent pain present in a single joint. Pain response develops 1 day post-induction. Readouts available are clinical signs and scoring, body weights, mechanical and thermal stimuli, weight bearing, histology and cytokine analysis.

Monoarthritic Pain

In addition to the monoarthritic pain model, MD Biosciences offers the traditional Adjuvant-induced arthritis model that allows for traditional pain measurements as well as a record of spontaneous pain using the Foot Print of Pain method. Other Arthritis models and research reagents include the Collagen Induced Arthritis (CIA) and Collagen Antibody Induced Arthritis (CAIA), ArthritoMab™ Arthritogenic Antibody Cocktail, Collagen Reagents, Collagen Antibodies and Collagen-related ELISA Kits and Assays.

About MD Biosciences
MD Biosciences provides products and pre-clinical services for companies engaged in inflammations and neurology research. The company is headquartered in Switzerland and has specialized laboratories located in the United States, United Kingdom, and Israel. A panel of scientific experts provides companies’ in-depth expertise and technologies to tackle problems and provide flexible drug discovery solutions, enabling smarter results faster.

###

The information in this press release should be considered accurate only as of the date of the release. MD Biosciences has no intention of updating and specifically disclaims any duty to update the information in these press releases.

Read More

Topics: Pain, Inflammation, Arthritis